Some top Moderna executives also drew criticism for selling shares worth millions, including Bancel and the firm’s chief medical officer, Tal Zaks. Everybody in the know actually just shakes their heads.”. Find out more about cookies Jessica Kourkounis for the Boston Globe. Curated profile of Derrick Rossi, CEO, Convelo Therapeutics including career history, news and intelligence, portfolio companies and investments. In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi.Rossi had developed a method of modifying mRNA by first transfecting it into human cells, then dedifferentiating it into stem cells which could then be further redifferentiated into desired target cell types. “We consider ourselves an immunotherapy company.”. What happened at the two-hour meeting and in the days that followed has become the stuff of legend — and an ego-bruising squabble. Moderna’s facility in Norwood, Mass. And even though the studies by Karikó and Weissman went unnoticed by some, they caught the attention of two key scientists — one in the United States, another abroad — who would later help found Moderna and Pfizer’s future partner, BioNTech. Derrick Rossi. And it was the starter pistol for the vaccine sprint to come. That’s Exactly the Plan. Moderna, a 10-year-old biotech company with billions in market valuation but no approved products, is racing forward with a vaccine of its own. Whether mRNA vaccines succeed or not, their path from a gleam in a scientist’s eye to the brink of government approval has been a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash into the biotech industry. of Stem Cell and Regenerative Biology Harvard Medical School Principal Faculty Harvard Stem Cell Institute Investigator Immune Disease Institute Program in Cellular and Molecular Medicine Children’s Hospital Boston 200 Longwood Avenue WAB Room #253 Boston, Massachusetts 02115 tel: 617.713.8900 Listen To Elon Musk Talk About Synthetic mRNA & Where It's Heading! Four months later, the British pharmaceutical giant AstraZeneca agreed to pay Moderna a staggering $240 million for the rights to dozens of mRNA drugs that did not yet exist. BoxRec.com uses cookies to make the site simpler. The U.S. government’s Operation Warp Speed program, which has underwritten the development of Moderna’s vaccine and pledged to buy Pfizer’s vaccine if it works, is “weighted toward technology platforms that have never made it to licensure before.”. “When you get money from someone, that always comes with strings.”. Soon, its vaccine became the first to undergo testing on humans, in a small early-stage trial. Derrick Rossi is an Assistant Professor in the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University. Both vaccines require two shots a few weeks apart. “We are now entering the age of mRNA therapeutics,” said Derrick Rossi, a former Harvard University stem-cell biologist who helped found Moderna in 2010. Despite the squabbling that followed the birth of Moderna, other scientists also saw messenger RNA as potentially revolutionary. Each is well-aware of the other in the race to be first. “Usually, at that point, people just say goodbye and leave because it’s so horrible,” Karikó said. “I asked her if Pfizer was interested in teaming up with us, and she, without any discussion, said, ‘Yes, we would love to do that,’” Sahin recalled. A native of Turkey, Ugur Sahin moved to Germany after his father got a job at a Ford factory in Cologne. Over in Germany, Sahin, the head of BioNTech, said a Lancet article in January about the outbreak in Wuhan, an international hub, galvanized him. The biotech had no scientific publications to its name and hadn’t shared a shred of data publicly. The company’s other co‐ founder, Derrick Rossi, was born in Canada and is here on an H-1B visa. Warning! Damian Garde covers biotech from New York for STAT. He lives in Providence. Pfizer began its late-stage trial on July 27 — the same day as Moderna — with the first volunteers receiving injections at the University of Rochester. By 1995, after six years on the faculty at the University of Pennsylvania, Karikó got demoted. That works out to roughly $25 a dose, which Moderna acknowledges includes a profit. ... Dr. Derrick Rossi, and Dr. … Just once a year we appeal to you to contribute to make it possible to continue this work. View the profiles of people named Derrick Rossi. BTW I'm against Trump's support of the vaccine! Derrick Rossi, one of Moderna’s co-founders (he has left the company) says she and her collaborator Drew Weissman deserve the Nobel Prize in chemistry. “We are now entering the age of mRNA therapeutics,” said Derrick Rossi, a former Harvard University stem-cell biologist who helped found Moderna in 2010. Even now, as Moderna and Pfizer test their vaccines on roughly 74,000 volunteers in pivotal vaccine studies, many experts question whether the technology is ready for prime time. Founders: Noubar Afeyan, Robert Langer, Kenneth Chien, Derrick Rossi Launched: 2010 Funding: $863.9 million Valuation: $3 billion Disrupting: Pharmaceuticals, biotechnology ... CEO … Covid-19 vaccines raise hope for cancer, throw open new field of medicine. “I think you could make new drugs, new vaccines — everything.”. Pat Greenhouse/the Boston Globe. Rossi thought he might be able to sidestep the controversy. About Derrick Rossi in brief. The next day, he met with his leadership team. Professor of Medical Microbiology of University of Leeds, R&D in Biotech, Environmental and various industries (no marketing product yet). “It’s total malarkey,” said Rossi, who ended his affiliation with Moderna in 2014. Convelo Therapeutics has 3 current team members, including President & CEO Derrick Rossi. But behind the scenes the company’s scientists were running into a familiar problem. Derrick J. Rossi (born 5 February 1966), is a Canadian stem cell biologist who is Associate Professor in the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University. He was also a Professor at Harvard Medical School and Harvard University, as well as an investigator at Boston Children’s Hospital where he led an academic team working on stem cell biology and regenerative medicine. The first volunteer to get a shot in Moderna’s late-stage trial was a television anchor at the CNN affiliate in Savannah, Ga., a move that raised eyebrows at rival vaccine makers. “I also thought maybe I’m not good enough, not smart enough. He also realized he needed a strong partner to manufacture the vaccine and thought of Pfizer. Its spokesperson Ray Jordan said Monday that executives suspected Pfizer would release some preliminary late-stage trial data before Moderna, in part because of the dosing schedule of the rival vaccines. Derrick Rossi received his B.Sc. “You have all these odd clinical and pathological changes caused by this novel bat coronavirus, and you’re about to meet it with all of these vaccines with which you have no experience,” said Paul Offit, an infectious disease expert at Children’s Hospital of Philadelphia and an authority on vaccines. Still, the soaring share prices of BioNTech and Moderna have made both Sahin and Bancel billionaires, according to Forbes. On a May afternoon in 2010, Rossi and Springer visited Langer at his laboratory in Cambridge. It all made sense on paper. Meanwhile BioNTech has often acted like the anti-Moderna, garnering far less attention. The couple have long been interested in immunotherapy, which harnesses the immune system to fight cancer and has become one of the most exciting innovations in medicine in recent decades. After isolating the virus from patients, Chinese scientists on Jan. 10 posted online its genetic sequence. He trained as a post-doctoral fellow at Stanford University from 2003-2007. Concurrently, Convelo Therapeutics announced that biotech pioneer Derrick Rossi, PhD was appointed as President and CEO. Pfizer CEO Albert Bourla, who rose through the ranks after more than 25 years with the company, said in a September interview with “Face the Nation” that if the Pfizer-BioNTech vaccine fails, his company will absorb the financial loss. There is nothing remarkable about the container, which could fit in a walk-in closet, except that its contents could end up in the world’s first authorized Covid-19 vaccine. “And it came back always no, no, no.”. Convelo Therapeutics has 3 current team members, including President & CEO Derrick Rossi. So has a brash, young rival just 23 miles away in Cambridge, Mass. Chinese researchers soon identified 41 hospitalized patients with the disease. He also co-hosted a daily magazine show for the NPR station in Rhode Island. Despite his role as CEO, Sahin has largely maintained the air of an academic. “We remain on track.”. After a decade of trial and error, Karikó and her longtime collaborator at Penn — Drew Weissman, an immunologist with a medical degree and Ph.D. from Boston University — discovered a remedy for mRNA’s Achilles’ heel. Derrick Rossi, a native of Toronto who rooted for the Maple Leafs and sported a soul patch, was a 39-year-old postdoctoral fellow in stem cell biology at Stanford University in 2005 when he read the first paper. Moderna was especially well-positioned for this moment. Dr. Rossi is the founder of Moderna Therapeutics, and co-founder of Intellia Therapeutics, Magenta Therapeutics, and Stelexis Therapeutics. She was back to the lower rungs of the scientific academy. Gradually, biotech’s self-proclaimed disruptor became a vaccines company, putting its experimental drugs on the back burner and talking up the potential of a field long considered a loss-leader by the drug industry. The package held a few hundred vials, each containing the experimental vaccine. Every strand of mRNA is made up of four molecular building blocks called nucleosides. Derrick Rossi CEO Convelo Therapeutics, Former Associate Professor at Boston Children's Hospital and Harvard Medical School Newton Center, Massachusetts 10 connections “This could be the most successful company in history,” he remembered telling her, even though no company existed yet. But J&J, which collaborated with Beth Israel Deaconess Medical Center’s Center for Virology and Vaccine Research and is also in a late-stage trial, has promised not to profit off sales of the vaccine during the pandemic. Thank you for your continued support. Derrick Rossi. Karikó had recently endured a cancer scare, and her husband was stuck in Hungary sorting out a visa issue. But Moderna didn’t provide any backup data, making it hard to assess how encouraging the results were. We look forward to providing you with even more cutting-edge market research, as Topio Networks. Moderna’s promise — and the more than $2 billion it raised before going public in 2018 — hinged on creating a fleet of mRNA medicines that could be safely dosed over and over. In 2013, the firm began disclosing its ambitions to transform the treatment of cancer and soon announced a series of eight partnerships with major drug makers. degrees from the University of Toronto, Canada in the 1990s, and his Ph.D. from the University of Helsinki, Finland, followed by post-doctoral training at Stanford University. The stumbling block, as Karikó’s many grant rejections pointed out, was that injecting synthetic mRNA typically led to that vexing immune response; the body sensed a chemical intruder, and went to war. “That’s the thing Noubar has used to turn Flagship into a big company, and he says it was totally his idea,” Rossi said. For the first five years, the firm operated in what Sahin called “submarine mode,” issuing no news releases, and focusing on scientific research, much of it originating in his university lab. Who is Moderna Inc.? Yet it somehow convinced investors and multinational drug makers that its scientific findings and expertise were destined to change the world. He would use modified messenger molecules to reprogram adult cells so that they acted like embryonic stem cells. Katalin Karikó spent the 1990s collecting rejections. Other executives include Derrick Rossi, President and Chief Executive Officer, Director; Samantha Stubblefield, Director of Research; and 4 others. Harvard University professor Dr. Derrick Rossi founded Moderna in 2010 to manufacture his research-based therapeutics, according to a 2014 interview with the Journal of Young Investigators. Its new sprawling drug-making facility nearby is hiring workers at a fast clip in the hopes of making history — and a lot of money. Dr. Rossi is an Associate Professor in … In fact, in 2013, the company hired Karikó as senior vice president to help oversee its mRNA work. “We understood that this would become a pandemic,” he said. Rossi co-founded Moderna, Intellia Therapeutics, Magenta Therapeox, and Stelexis Therapeutic. Now the work to which she’d devoted countless hours was slipping through her fingers. Under Bancel’s leadership, Moderna would raise more than $1 billion in investments and partnership funds over the next five years. Forty-two days after the genetic code was released, Moderna’s CEO Bancel opened an email on Feb. 24 on his cellphone and smiled, as he recalled to the Globe. Blood samples from volunteers participating in Moderna’s Phase 3 Covid-19 vaccine trial wait to be processed in a lab  at the University of Miami Miller School of Medicine. When BioNTech went public last October, it raised $150 million, and closed with a market value of $3.4 billion — less than half of Moderna’s when it went public in 2018. And on July 28, it became the first to start getting tested in a late-stage trial in a scene that reflected the firm’s receptiveness to press coverage. Soon after, the then named ‘Moderna Therapeutics’ was formed, Rossi … Vor, the Norse goddess of wisdom, was known as “the careful one.” These qualities are reflected in Vor’s ability to leverage the cumulative knowledge around a variety of recent technologies to carefully craft a new generation of HSCs that are hidden from targeted therapies. Some experts worry about injecting the first vaccine of this kind into hundreds of million of people so quickly. degrees from the University of Toronto, Canada in the 1990s, and his Ph.D. from the University of Helsinki, Finland in 2003. Related: Four reasons for encouragement based on Pfizer’s Covid-19 vaccine results, Related: Selling stock like clockwork, Moderna’s top doctor gets $1 million richer every week, Related: The Road Ahead: Charting the coronavirus pandemic over the next 12 months — and beyond, Related: Covid-19 Drugs and Vaccines Tracker, Related: In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics — and getting results. “I thought of going somewhere else, or doing something else,” Karikó said. Rossi peered through the lens and saw something extraordinary: a plate full of the very cells he had hoped to create. “Karikó and Weissman figured out that if you incorporate modified nucleosides into mRNA, you can kill two birds with one stone.”. At least 400 drug and medical device companies have licensed his patents. It was a real obstacle, and still may be, but Karikó was convinced it was one she could work around. Striking a magnanimous note, he described Pfizer’s news as “an important step for mRNA medicine.”, “We’ve said that the world needs more than one Covid-19 vaccine,” Jordan said. But using those cells for research had created an ethical firestorm because they are harvested from discarded embryos. Derrick Rossi, a native of Toronto who rooted for the Maple Leafs and sported a soul patch, was a 39-year-old postdoctoral fellow in stem cell biology at Stanford University in 2005 when he read the first paper. In animal studies, the ideal dose of their leading mRNA therapy was triggering dangerous immune reactions — the kind for which Karikó had improvised a major workaround under some conditions — but a lower dose had proved too weak to show any benefits. In the natural world, the body relies on millions of tiny proteins to keep itself alive and healthy, and it uses mRNA to tell cells which proteins to make. On May 18, Moderna issued a press release trumpeting “positive interim clinical data.” The firm said its vaccine had generated neutralizing antibodies in the first eight volunteers in the early-phase study, a tiny sample. I think it's the biggest mistake he's made. Before messenger RNA was a multibillion-dollar idea, it was a scientific backwater. He previously covered the federal and state courts and then spent six years on the Spotlight Team. It is a story that began three decades ago, with a little-known scientist who refused to quit. “The whole world has seen this. Philip Dormitzer, chief scientific officer for viral vaccines at Pfizer, said developing a coronavirus vaccine is “very much in Pfizer’s comfort zone as a vaccine company with multiple vaccine products.”. “I worry about innovation at the expense of practicality,” Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine and an authority on vaccines, said recently. Rather, the federal government will pay the partners $1.95 billion for at least 100 million doses if the vaccine gets approved. Along with those achievements, Moderna has repeatedly stirred controversy. Derrick Rossi, one of Moderna’s co-founders (he has left the company) says she and her collaborator Drew Weissman deserve the Nobel Prize in chemistry. and M.Sc. He is a principal faculty member of the Harvard Stem Cell Institute and he is also an investigator at the Immune Disease Institute (IDI), and the Program in Cellular and Molecular Medicine at Children’s Hospital Boston. In a 2012 Moderna news release, Afeyan said the firm’s “promise rivals that of the earliest biotechnology companies over 30 years ago — adding an entirely new drug category to the pharmaceutical arsenal.”. His efforts in the development of cutting edge technologies and new therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Up popped a photograph of a box placed inside a refrigerated truck at the Norwood plant and bound for the National Institute of Allergy and Infectious Diseases in Bethesda, Md. He was also a runner-up for other awards, including a Pulitzer Prize and Goldsmith Prize for Investigative Reporting, for a series of stories about dangerous off-campus housing for college students in Boston. Derrick Rossi, 2008. His wife, Özlem Türeci had, as a child, followed her father, a surgeon, on his rounds at a Catholic hospital. That raised concerns that the virus might have leaped from an animal, possibly a bat, to humans. It is called synthetic messenger RNA, an ingenious variation on the natural substance that directs protein production in cells throughout the body. and M.Sc. He still uses his university email address and rides a 20-year-old mountain bicycle from his home to the office because he doesn’t have a driver’s license. He is the CEO of ConveloTherapeutics. Time magazine named Dr. Rossi as one of the 100 Most Influential People in the world (Time 100) in 2011. Taimy Alvarez / AP. It announced its promising early results from that trial on Monday, and hopes to have sufficient data this month to seek emergency use authorization of the vaccine for at least some high-risk people. Although relatively easy and quick to produce compared to traditional vaccine-making, no mRNA vaccine or drug has ever won approval. Derrick Rossi received his B.Sc. But Rossi didn’t have vaccines on his mind when he set out to build on their findings in 2007 as a new assistant professor at Harvard Medical School running his own lab. Alex Hogan / STAT, Shortly before midnight, on Dec. 30, the International Society for Infectious Diseases, a Massachusetts-based nonprofit, posted an alarming report online. Biotech company Moderna, co-founded by HSCI scientist Derrick Rossi, is set to bring a new class of treatments to patients. Like Moderna, BioNTech licensed technology developed by the Pennsylvania scientist whose work was long ignored, Karikó, and her collaborator, Weissman. Researchers understood its role as a recipe book for the body’s trillions of cells, but their efforts to expand the menu have come in fits and starts. Its U.S. headquarters is in Cambridge. Her work, attempting to harness the power of mRNA to fight disease, was too far-fetched for government grants, corporate funding, and even support from her own colleagues. He ended his affiliation with the company in 2014. That discovery, described in a series of scientific papers starting in 2005, largely flew under the radar at first, said Weissman, but it offered absolution to the mRNA researchers who had kept the faith during the technology’s lean years. And, worse, the resulting biological havoc might stir up an immune response that could make the therapy a health risk for some patients. Justin Ide / Harvard University Highs: Working in the promising and still-controversial field of stem cell research, Rossi discovered an innovative method for reprogramming skin cells back into stem cells. Founded and run by Noubar Afeyan, a swaggering entrepreneur, the Cambridge venture capital firm has created dozens of biotech startups. Number of Current Team Members 3. Part of a "freezer farm," a football field-sized facility for storing finished Covid-19 vaccines, under construction in Kalamazoo, Mich. Pfizer’s experimental vaccine requires ultracold storage, at about -70 C, Jeremy Davidson / Pfizer via AP, Material of Interest to People on the Left, The Story of mRNA: How a Once-Dismissed Idea Became a Leading Technology in the Covid Vaccine Race, Damian Garde (STAT), Jonathan Saltzman (Boston Globe), ‘Natural Immunity’ From Covid Is Not Safer Than a Vaccine, Open Source Licensing for Covid-19 Vaccines, Why Democrats Keep Losing Rural Counties Like Mine, Joe Biden’s Neera Tanden Pick Is Even Worse Than You Thought, The Supreme Court Wants to Revive a Doctrine That Would Paralyze Biden’s Administration. Stéphane Bancel, Moderna’s CEO, also immigrated to America (from France) for grad school. Recognizing the commercial potential, Springer contacted Robert Langer, the prolific inventor and biomedical engineering professor at the Massachusetts Institute of Technology. Founded 2010, by stem cell biologist Derrick Rossi, who was hailed by Time magazine as one of the 100 most influential people of 2011 for a novel stem-cell treatment. He spent four years covering drug development at FierceBiotech, and previously wrote for Patch.com and the Albuquerque Journal. “I told them that we have to deal with a pandemic which is coming to Germany,” Sahin recalled. In Mainz, Germany, situated on the left bank of the Rhine, another new company was being formed by a married team of researchers who would also see the vast potential for the technology, though vaccines for infectious diseases weren’t on top of their list then. Recipients of Pfizer’s vaccine get two doses three weeks apart, while recipients of Moderna’s get two doses four weeks apart. Aram Boghosian for STAT. ... Dr. Derrick Rossi, and Dr. … “That fundamental discovery is going to go into medicines that help the world.”, Derrick Rossi, one of the founders of Moderna, in his Newton, Mass., home. Derrick Rossi President & CEO. The companies’ focus on vaccines could not have been more fortuitous. “If anyone asks me whom to vote for some day down the line, I would put them front and center,” he said. “I wanted to liberate our scientists from any bureaucracy,” he said. But in its altered, synthetic form, one of those building blocks, like a misaligned wheel on a car, was throwing everything off by signaling the immune system. Vendors sold live wild animals, from bamboo rats to ostriches, in crowded stalls. He was part of a team that won a George Polk Award in 2012 for a series on the state’s unusually high rate of acquittal at bench trials for drunk driving. We want to make sure you get the most out of our platform. Damian spends his free time watching movies and shouting at the New York Knicks through screens of various sizes. Convelo Therapeutics's Co-Founder, Director is Paul Tesar. And for the Hungarian-born scientist behind a key mRNA discovery, it was a career dead-end. from University of Toronto, and his PhD from the University of Helsinki. He wondered whether modified messenger RNA might hold the key to obtaining something else researchers desperately wanted: a new source of embryonic stem cells. BioNTech executives haven’t sold any shares since the company went public last year, according to Securities and Exchange Commission records. Unlike Moderna, the firm has published its research from the start, including about 150 scientific papers in just the past eight years. That became BioNTech, another blended name, derived from Biopharmaceutical New Technologies. Because companies that work with messenger RNA don’t need the virus itself to create a vaccine, just a computer that tells scientists what chemicals to put together and in what order, researchers at Moderna, BioNTech, and other companies got to work. Kariko was a scientist working on synthesizing RNA at the University of Szeged in Hungary, her home country. In 2010, Time magazine cited one of Rossi’s discoveries as one of the top ten medical breakthroughs of the year. Suzanne Kreiter/the Boston Globe. Mark Arsenault of the Globe staff contributed reporting. The two companies had worked together before to try to develop mRNA influenza vaccines. Dr. Rossi is the founder of Moderna Therapeutics, and co-founder of Intellia Therapeutics, Magenta Therapeutics, and Stelexis Therapeutics. Click here to check it out. Top executives at Pfizer also have sold far less stock compared to Moderna since the pandemic began. In particular, they were tantalized by the possibility of creating personalized vaccines that teach the immune system to eliminate cancer cells. Summary Derrick Rossi’s research into using mRNA as a new kind of therapeutic was initially supported by HSCI seed funding, and gave rise to biotech company Moderna Therapeutics. I tried to imagine: Everything is here, and I just have to do better experiments.”, Katalin Karikó, a senior vice president at BioNTech overseeing its mRNA work, in her home office in Rydal, Penn. Not only did he recognize it as groundbreaking, he now says Karikó and Weissman deserve the Nobel Prize in chemistry. Please help. If you could design your own mRNA, you could, in theory, hijack that process and create any protein you might desire — antibodies to vaccinate against infection, enzymes to reverse a rare disease, or growth agents to mend damaged heart tissue.